According to a new report by GBI Research, the development of new diabetes medications is now most often the result of deals between companies. The report, Diabetes Therapeutics Market to 2017 - Better Glycemic Control and Reduced Potential Risk of Hypoglycemia to Increase the Market Share of DPP-IV Inhibitors and GLP-1 Agonists, found that while major companies account for significant shares of the market, smaller companies are more able to compete using new strategies arising from mergers, acquisitions, licensing deals and cooperation within the market, which is expected to boost product development until at least 2017.
展开▼
